TY - JOUR T1 -再治疗方案失败不能预测MDR/XDR结核病:“盲目”治疗危险吗?JF -欧洲呼吸杂志JO - Eur Respir J SP - 1283 LP - 1285 DO - 10.1183/09031936.00144710 VL - 37 IS - 5 AU - Badoum, G. AU - Saleri, N. AU - Dembélé， M.S. AU - Ouedraogo, M. AU - Pinsi, G. AU - Boncoungou, K. AU - Bonkoungou, V. AU - Birba, E. AU - Miotto, P. AU - Migliori, G.B. AU - Cirillo, D.M. AU - Matteelli，A. Y1 - 2011/05/01 UR - //www.qdcxjkg.com/content/37/5/1283.abstract N2 -致编辑:耐多药结核病(MDR)和广泛耐药结核病(XDR)是全球新出现的公共卫生威胁1。已修订了控制结核战略，以便在2015年2-4之前为所有耐多药结核患者普遍提供诊断和治疗。该计划要求加快获得结核分枝杆菌培养、种类鉴定和结核分枝杆菌药敏试验(DST)。然而，在一些国家，适当的结核病实验室设施在很大程度上仍然缺乏。在缺乏培养和DST的情况下，在假设≥80%的结核患者携带耐多药结核分枝杆菌菌株的前提下，再治疗方案失败的结核病患者被认为有资格接受二线药物治疗方案5。在布基纳法索，与大多数低收入和部分中等收入国家一样，未采用标准二类方案的肺结核病例只有在治疗第五个月结束时通过痰涂片镜检阳性才能确定，并被定义为“慢性”结核病患者。慢性结核病的诊断具有重要意义。布基纳法索慢性结核病病例管理国家指南建议住院和住院治疗≥6个月，采用标准化的IV类治疗方案6。Although the diagnosis of chronic TB is taken as a surrogate marker for the identification of MDR-TB, little evidence is available from the literature on its positive predictive value for MDR-TB diagnosis. We systematically performed microbiological investigations, which included both phenotypic and genotypic techniques, on all newly identified chronic TB cases diagnosed over a 2-yr period in Burkina Faso. Here, we report the results and discuss the implications that “blind” treatment with second-line drugs have at programmatic level.A prospective, country-wide investigation was performed to microbiologically characterise all consecutively registered chronic TB cases in Burkina Faso, defined on the basis of … ER -